Items where Author is "Lawson, Kim"

LAWSON, Kim (2016). Potential drug therapies for the treatment of fibromyalgia. Expert opinion on investigational drugs, 1-11. [Article]

ERGISI, Mehmet, LAW, Alexander, CHAUDHARI, Nishant, TSATSARI, Stefania, LAWSON, Kim and JENNER, Christopher (2023). Effectiveness of topical gabapentin in the treatment of vulvodynia: a narrative synthesis. Frontiers in Pain Research, 4: 1159268. [Article]

LAWSON, Kim (2023). What is the progress of experimental drug development for fibromyalgia? Expert Opinion on Investigational Drugs. [Article]

FURNESS, Penelope, SHELTON, Tom, BERESFORD, Ruth, LAWSON, Kim, TAYLOR, Sophie and HAYWOOD-SMALL, Sarah (2023). Physiotherapy for fibromyalgia: a phenomenological study of patients’ experiences. Journal of Pain Management, 15 (4). [Article]

FURNESS, Penny, SHELTON, Tom, BERESFORD, Ruth, LAWSON, Kim, TAYLOR, Sophie and HAYWOOD-SMALL, Sarah (2023). Remote care for chronic pain: A qualitative evaluation with managers, practitioners and patients. Journal of Pain Management, 15 (4). [Article]

LAWSON, Kim (2022). Identification of the Involvement of Potassium Channels in Fibromyalgia. Frontiers in Bioscience-Scholar, 14 (4): 29. [Article]

PIRAGINE, Eugenia, CITI, Valentina, LAWSON, Kim, CALDERONE, Vincenzo and MARTELLI, Alma (2022). Potential Effects of Natural H2S-Donors in Hypertension Management. Biomolecules, 12 (4): 581. [Article]

PIRAGINE, Eugenia, CITI, Valentina, LAWSON, Kim, CALDERONE, Vincenzo and MARTELLI, Alma (2022). Potential effects of natural H 2 S-Donors in Hypertension Management. Biomolecules, 12 (4): 581. [Article]

LAWSON, Kim, SINGH, Attam, KANTSEDIKAS, Ilya, JENNER, Christopher Arthur and AUSTEN, Daniel Keith (2021). Flupirtine as a Potential Treatment for Fibromyalgia. Journal of Exploratory Research in Pharmacology. [Article]

TAYLOR, Sophie, FURNESS, Penny, ASHE, Simon, HAYWOOD-SMALL, Sarah and LAWSON, Kim (2021). Comorbid Conditions, Mental Health and Cognitive Functions in Adults with Fibromyalgia. Western Journal of Nursing Research, 43 (2), 115-122. [Article]

LAWSON, Kim (2020). Sleep Dysfunction in Fibromyalgia and Therapeutic Approach Options. OBM Neurobiology, 4 (1), p. 16. [Article]

LAWSON, Kim (2019). Is there a role for melatonin in fibromyalgia? AIMS Molecular Science, 6 (4), 73-86. [Article]

LAWSON, Kim (2019). Pharmacology and clinical applications of flupirtine: Current and future options. World journal of pharmacology, 8 (1), 1-13. [Article]

LAWSON, Kim (2018). Kv7 channels a potential therapeutic target in fibromyalgia: A hypothesis. World Journal of Pharmacology, 7 (1), 1-9. [Article]

TAYLOR, Sophie, STEER, Michael, ASHE, Simon, FURNESS, Penny, HAYWOOD-SMALL, Sarah and LAWSON, Kim (2018). Patients' perspective of the effectiveness and acceptability of pharmacological and non-pharmacological treatments of fibromyalgia. Scandinavian Journal of Pain. [Article]

FURNESS, Penny, VOGT, Katharina, ASHE, Simon, TAYLOR, Sophie, HAYWOOD-SMALL, Sarah and LAWSON, Kim (2018). What causes Fibromyalgia? An online survey of patient perspectives. Health Psychology Open, 5 (2). [Article]

ASHE, Simon, FURNESS, Penny, TAYLOR, Sophie, HAYWOOD-SMALL, Sarah and LAWSON, Kim (2017). A qualitative exploration of the experiences of living with and being treated for fibromyalgia. Health Psychology Open, 4 (2), 1-12. [Article]

LAWSON, Kim (2017). A brief review of the pharmacology of amitriptyline and clinical outcomes in treating fibromyalgia. Biomedicines, 5 (2), p. 24. [Article]

LAWSON, Kim (2017). Emerging pharmacological strategies for the treatment of fibromyalgia. World Journal of Pharmacology, 6 (1), 1-10. [Article]

ASHE, Simon, FURNESS, Penny, TAYLOR, Sophie, HAYWOOD-SMALL, Sarah and LAWSON, Kim (2016). "Not all in my head": a qualitative exploration of living with fibromyalgia and its treatments (Oral presentation). The European Health Psychologist, 18 (Supp), p. 695. [Article]

LAWSON, Kim (2016). Fibromyalgia pathogenesis provides drug target clues. Drug Target Review, 3, 45-49. [Article]

LAWSON, Kim (2014). Clinical trials for patients with fibromyalgia syndrome. Clinical & Experimental Pharmacology, 04 (05). [Article]

LAWSON, Kim (2018). Flupirtine is an effective analgesic: is the associated rare liver injury a limiting factor to its use? Anesthesia and Analgesia. [Article]

MARTELLI, A., TESTAI, L., BRESCHI, M.C., LAWSON, Kim, MCKAY, Neil, MICELI, F., TAGLIALATELA, M. and CALDERONE, V. (2013). Vasorelaxation by hydrogen sulphide involves activation of Kv7 potassium channels. Pharmacological Research, 70 (1), 27-34. [Article]

BEARD, S M, ROSKELL, N, LE, T K, ZHAO, Y, COLEMAN, A, ANG, D and LAWSON, Kim (2011). Cost effectiveness of duloxetine in the treatment of fibromyalgia in the United States. Journal of medical economics. [Article]

VAHABI, B, LAWSON, Kim, MCKAY, Neil and SELLERS, Donna (2011). Phasic activity of urinary bladder smooth muscle in the streptozotocin-induced diabetic rat: effect of potassium channel modulators. European Journal of Pharmacology, 660 (2-3), 431-437. [Article]

PUTTINI, P. Sarzi, HÄUSER, W., LAWSON, Kim and SPROTT, H. (2009). 11 Topical Seminar Summary: FIBROMYALGIA SYNDROME. European Journal of Pain, 13, S5-S6. [Article]

VAHABI, B, LAWSON, Kim, MCKAY, Neil and SELLERS, Donna (2009). Cholinergic modulation of spontaneous activity in bladder strips from the diabetic rat : effect of the mucosa. European Eurology Supplements, 8 (4), p. 177. [Article]

VAHABI, B., MCKAY, Neil, LAWSON, Kim and SELLERS, Donna (2008). Identification of C-Kit positive cells in rat urinary bladder and characterization of their functional role in spontaneous activity in control and diabetic bladders. European Eurology Supplements, 7 (3), p. 181. [Article]

SELLERS, Donna, MCKAY, Neil and LAWSON, Kim (2008). Inhibitory effect of cromakalim on muscarinic receptor-stimulated spontaneous activity in diabetic rat bladder. Fundamental & Clinical Pharmacology, 22 (Suppl), p34. [Article]

MCKAY, Neil, KIRBY, R W and LAWSON, Kim (2008). Rubidium efflux as a tool for the pharmacological characterisation of compounds with BK channel opening properties. In: LIPPIAT, Jonathan D, (ed.) Potassium channels : methods and protocols. Methods in Molecular Biology (491). Humana Press, 267-277. [Book Section]

LAWSON, Kim (2007). Are complex therapies required as pharmacological treatments of fibromyalgia? Future Rheumatology, 2 (6), 599-605. [Article]

LAWSON, Kim (2006). Emerging pharmacological therapies for fibromyalgia. Current Opinion in Investigational Drugs, 7 (7), 631-636. [Article]

LAWSON, Kim (2006). Potassium channels as targets for the management of pain. Central Nervous System Agents in Medicinal Chemistry, 6 (2), 119-128. [Article]

LAWSON, Kim (2002). Tricyclic antidepressants and fibromyalgia: what is the mechanism of action? Expert opinion on investigational drugs, 11 (10), 1437-1445. [Article]

LAWSON, Kim and DUNNE, Mark J. (2001). Peripheral channelopathies as targets for potassium channel openers. Expert opinion on investigational drugs, 10 (7), 1345-1359. [Article]